Philippe Martin

Philippe Martin is the Chief R&D Officer of Viatris. He joined the company in September 2023.

Philippe is a highly experienced R&D leader with demonstrated success in building and leading high-performing R&D organizations. He has more than 25 years of experience developing and commercializing innovative and transformational therapies across multiple therapeutic areas and modalities ranging from small molecules to highly innovative biologics and cell therapies.

Before joining Viatris, Philippe was Chief of R&D at BioAtla, a global biotechnology company that develops novel therapies for cancer treatment. Philippe previously served at Celgene for nearly 10 years where his roles expanded from Executive Director, Project Leadership – in which he led development and commercialization of the blockbuster drugs Otezla® and Zeposia® – to Corporate Vice President, in which he oversaw the company pipeline in early and late development in the fields of inflammation and immunology, neurology, oncology, hepatology and gastroenterology, including the execution of large Phase 3 clinical studies. Prior to Celgene, Philippe held multiple positions of increasing responsibility at Schering-Plough and Aventis & Solvay.

Philippe earned a master’s degree in organic chemistry from Pierre and Marie Curie University in Paris and a Master of Business Administration from emlyon business school in Lyon, France.